MDxHealth sees FY25 revenue $108M-$110M, consensus $98.93M

Backs FY25 view of adjusted EBITDA profitability in the first half of this year. Michael McGarrity, CEO of MDxHealth (MDXH), commented: “We are pleased to report continued execution on our growth strategy, with year-over-year revenue growth of approximately 28%. We are confident that the strength of our sales channel coupled with our expanded menu offering to our urology customer base will continue to drive sustainable growth. Based on our operating discipline, commercial execution, and the underlying growth of our end markets, we anticipate 2025 revenue of $108-110 million, which would represent year-over-year revenue growth of approximately 20-22%.”